Mangoceuticals (MGRX)

Nasdaq Markedet er åpent

Mangoceuticals, Inc. er et selskap innen menns velvære som markedsfører helseprodukter og -tjenester gjennom en telemedisinsk modell. Selskapets kommersielle tilnærming er bygget rundt direkte tilgang til forbrukeren, digital kunderegistrering og utlevering via apotek, noe som gjør det mulig for pasienter å søke behandling på en diskret måte uten å være avhengige utelukkende av tradisjonelle, fysiske helsetjenester.

Det mest kjente tilbudet er knyttet til menns seksuelle helse, inkludert Mango ED-merkede produkter, som kan forskrives etter en telehelsekonsultasjon der det er hensiktsmessig. Selskapet selger ikke bare reseptfrie varer; plattformen er utformet for å koble forbrukere med autoriserte medisinske behandlere og, når en resept utstedes, med apotekpartnere som håndterer ekspedering og distribusjon. Denne strukturen plasserer Mangoceuticals i det voksende markedet for digital helse, der bekvemmelighet, personvern og forbrukerrettet merkevarebygging er viktige deler av kundeopplevelsen.

Mangoceuticals fokuserer på velværeområder som ofte er underdekket i tradisjonell markedsføring av helsetjenester, eller som er forbundet med stigma for forbrukerne. Ved å bruke en nettbasert modell søker selskapet å redusere friksjon innen områder som erektil dysfunksjon og relaterte bekymringer innen menns helse. Virksomheten er avhengig av digital markedsføring, kundeanskaffelse, etterlevelse av regelverk, relasjoner med apotek og evnen til å opprettholde tillit rundt medisinske konsultasjoner og håndtering av resepter.

Selskapet opererer i et konkurransepreget marked som omfatter telehelseplattformer, nettapotek, farmasøytiske merkevarer og spesialister på menns helse. For investorer representerer Mangoceuticals eksponering mot en mindre virksomhet innen forbrukerhelse og telemedisin, snarere enn en diversifisert farmasøytisk produsent. Utsiktene er knyttet til merkevarekjennskap, produktutvidelse, pasientbevaring og bredere bruk av helsetjenester på nett.

0.38 USD
+0.01 (+3.71%)

Sist oppdatert

Markedsverdi
6.52M
P/E-tall
P/FCF-tall
P/S-tall
15.74
Selskapsverdi
6.35M
Sektor
Bransje
Adresse
15110 DALLAS PKWY, SUITE 600, DALLAS, TX, 75248
GlobeNewswire Inc.

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

17. mars 2026, 21:00 P.M.
GlobeNewswire Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

06. mars 2026, 22:00 P.M.
GlobeNewswire Inc.

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

14. nov. 2025, 01:37 A.M.
GlobeNewswire Inc.

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

25. apr. 2025, 15:00 P.M.
Investing.com

Azz Inc. COO acquires $21.2k in company stock By Investing.com - Investing.com Australia

12. juli 2024, 20:11 P.M.
GlobeNewswire Inc.

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

06. juni 2024, 14:30 P.M.
GlobeNewswire Inc.

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

04. juni 2024, 22:00 P.M.
GlobeNewswire Inc.

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

23. mai 2024, 14:30 P.M.
PennyStocks

Spotting Penny Stocks Before They Explode, Top Tips

22. mai 2024, 12:52 P.M.
GlobeNewswire Inc.

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

16. mai 2024, 22:40 P.M.
GlobeNewswire Inc.

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

12. apr. 2024, 14:45 P.M.
GlobeNewswire Inc.

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

05. feb. 2024, 14:50 P.M.
GlobeNewswire Inc.

MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

19. jan. 2024, 14:00 P.M.
GlobeNewswire Inc.

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

15. des. 2023, 16:39 P.M.
GlobeNewswire Inc.

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

13. des. 2023, 13:30 P.M.
GlobeNewswire Inc.

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

29. nov. 2023, 14:30 P.M.
GlobeNewswire Inc.

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men’s Health Awareness Month

02. nov. 2023, 14:15 P.M.
GlobeNewswire Inc.

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

13. okt. 2023, 15:40 P.M.
GlobeNewswire Inc.

Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth

12. okt. 2023, 15:15 P.M.
GlobeNewswire Inc.

Mangoceuticals Brand MangoRx Announced as Raindance Film Festival’s Headline Sponsor

14. sep. 2023, 12:00 P.M.
Markedsverdi
6.52M
Selskapsverdi
6.35M
P/E-tall
P/B-tall
0.48
P/S-tall
15.74
EV / EBITDA-forhold
-0.44
EV / omsetning
15.31
Resultat per aksje
-1.17
Utbytterente
0%
P/FCF-tall
P/CF-tall
Fri kontantstrøm
Avkastning på egenkapital
-149.07%
Avkastning på eiendeler
-139.03%
Gjeld / egenkapital
0
Likviditetsgrad I
0.29
Likviditetsgrad II
0.29
Kontanter
0.24
Snittvolum
714.66K
Fundamentalpris (snapshot)
0.38

Resultatregnskap

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Omsetning 67.86K 94.36K 84.25K 168.11K 109.31K
Bruttofortjeneste 59.65K 47.48K 50.9K 89.95K 84.57K
Driftsresultat -1.76M -1.62M -7.54M -5.27M -3.81M
Driftsresultat før avskrivninger (EBITDA) -1.46M -1.04M -7.52M -4.43M -3.39M
Nettoresultat -3.7M -3.06M -7.91M -5.42M -5.13M
Grunnleggende EPS -0.22 -0.01 -0.69 -0.57 -1.12
Utvanet EPS -0.22 -0.01 -0.69 -0.57 -1.12

Balanse

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Sum eiendeler 14.45M 16.09M 16.53M 20.84M 21.75M
Sum gjeld 974.57K 890.57K 804.28K 1.6M 1.5M
Egenkapital 13.47M 15.2M 15.73M 19.24M 20.25M
Kontanter og ekvivalenter 174.56K 1.49M 481.28K 101.02K 76.5K
Omløpsmidler 212.47K 1.55M 598.22K 117.96K 176.65K
Kortsiktig gjeld 737.61K 890.57K 804.28K 1.6M 1.5M

Kontantstrøm

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Kontantstrøm fra drift -1.31M -1.08M -1.24M -1.26M -2.27M
Kontantstrøm fra investeringer
Kontantstrøm fra finansiering 2.08M 1.62M 1.28M 2.29M
Endring i kontanter -1.31M 1.01M 380.31K 24.34K 10.22K
Type Rapport Dato Lenke
edgar index 10-Q — MANGOCEUTICALS, INC. Vis rapport
edgar index NT 10-Q — MANGOCEUTICALS, INC. Vis rapport
edgar index 10-K — MANGOCEUTICALS, INC. Vis rapport
ten k section 10-K — business Vis rapport
ten k section 10-K — mda Vis rapport
ten k section 10-K — risk_factors Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index EFFECT — MANGOCEUTICALS, INC. Vis rapport
edgar index UPLOAD — MANGOCEUTICALS, INC. Vis rapport
edgar index CORRESP — MANGOCEUTICALS, INC. Vis rapport
edgar index S-1/A — MANGOCEUTICALS, INC. Vis rapport
edgar index S-1 — MANGOCEUTICALS, INC. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
edgar index 424B5 — MANGOCEUTICALS, INC. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
form 4 Form 4 — JOHNSTON EUGENE M Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
form 4 Form 4 — JOHNSTON EUGENE M Vis rapport
form 4 Form 4 — JOHNSTON EUGENE M Vis rapport
edgar index 144 — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 144 — MANGOCEUTICALS, INC. Vis rapport
form 4 Form 4 — Hamilton Alex P. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
edgar index 10-Q/A — MANGOCEUTICALS, INC. Vis rapport
edgar index 10-Q — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index SCHEDULE 13D/A — MANGOCEUTICALS, INC. Vis rapport
edgar index 8-K — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
edgar index 4 — MANGOCEUTICALS, INC. Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Tiger Cub Trust Vis rapport
form 4 Form 4 — Cohen Jacob D. Vis rapport
form 4 Form 4 — D'Alessio Lorraine Pamela Vis rapport
form 4 Form 4 — Hamilton Alex P. Vis rapport